Valo Health, a technology company being built to transform the drug discovery and development, completed the acquisition of TARA Biosystems, a cardiovascular disease biotechnology company. Financial terms were not disclosed. "This acquisition builds on Valo's unyielding commitment to identify new treatments for cardiovascular disease, creating a best-in-class end-to-end drug discovery and development platform aimed at accelerating the delivery of lifesaving drugs to the millions of patients suffering from cardiovascular diseases," David Berry, Valo founder and CEO.